Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer.
Dec 30, 2022 • 13 tweets • 12 min read
2022 was the year mutant KRAS in #PancreaticCancer truly became actionable.
Direct KRAS targeting & #PancreaticCancer, a 🧵:
In @NEJM by @DavidHongMD & colleagues:
Sotorasib in KRAS p.G12C–Mutated Advanced #PancreaticCancer nejm.org/doi/full/10.10…
G12C is ~1.6% of KRAS alleles in pancreatic cancer, & monotherapy responses in pre-treated patients are mostly transient stable disease, but a step forward.